Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07415824 · ClinicalTrials.gov registry record

Multiple Sclerosis Implementation Network (Registry)

A clinical trial of Multiple Sclerosis, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
2,000
Enrollment target
3
Study locations

NCT07415824: Recruiting study of Multiple Sclerosis, sponsored by The University of Texas Health Science Center, Houston.

NCT07415824 is a study of Multiple Sclerosis that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 2,000 participants, above the 579-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (245% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07415824, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
2,000 participants
Enrollment target
3
Study locations

Study Summary

The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life. This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.

Primary Outcome

Total score on the PDDS ranges from 0 (normal) to 8 (Bedridden: Unable to sit in a wheelchair for more than one hour), with a higher score indicating a worse outcome.

Conditions Studied

Study Locations (3)

Texas

  • The University of Texas at Austin - Austin
  • The University of Texas Health Science Center at Houston (UTHealth Houston) - Houston

New Jersey

  • Multiple Sclerosis Association of America - Cherry Hill

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2025-04-28
Est. Completion 2030-12-31

What NCT07415824 shows while recruiting

NCT07415824 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 579-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (245% higher).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT07415824 reports a single indexed study location in Texas, New Jersey.

Frequently Asked Questions

What is clinical trial NCT07415824 about?

NCT07415824 is a clinical study titled "Multiple Sclerosis Implementation Network (Registry)". The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Co...

What is the current status of trial NCT07415824?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2025-04-28. Estimated completion is 2030-12-31.

What conditions does trial NCT07415824 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT07415824?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07415824 being conducted?

This trial has 3 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07415824's enrollment target sits among peer trials

2,000 15th of 315 higher than 299 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07415824, the US trial registry maintained by the National Library of Medicine. NCT07415824 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.